Plant-Derived Natural Compounds for the Treatment of Amyotrophic
Lateral Sclerosis: An Update

Roohi       Mohi-ud-din; Reyaz    Hassan    Mir; Abdul    Jalil    Shah; Saba       Sabreen; Taha    Umair    Wani; Mubashir    Hussain    Masoodi; Esra    Küpeli    Akkol; Zulfiqar   Ali   Bhat; Haroon       Khan
Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease (MND) that typically causes death within 3-5 years after diagnosis. Regardless of the substantial scientific knowledge accrued more than a century ago, truly effective therapeutic strategies remain distant. Various conventional drugs are being used but are having several adverse effects.
Objective/Aim: The current study aims to thoroughly review plant-derived compounds with welldefined ALS activities and their structure-activity relationships. Moreover, the review also focuses on complex genetics, clinical trials, and the use of natural products that might decrypt the future and novel therapeutics in ALS.
Methods: The collection of data for the compilation of this review work was searched in PubMed Scopus, Google Scholar, and Science Direct.
Results: Results showed that phytochemicals like-Ginkgolides, Protopanaxatriol, Genistein, epigallocatechingallate, resveratrol, cassoside, and others possess Amyotrophic lateral sclerosis (ALS) activity by various mechanisms
Conclusion: These plant-derived compounds may be considered as supplements for conventional (ALS). Moreover, further preclinical and clinical studies are required to understand the structureactivity relationships, metabolism, absorption, and mechanisms of plant-derived natural agents.
Keywords: Plant-derived products, SOD1 mutations, CNS disorders, SAR, clinical trials, Therapeutic effects.
Graphical Abstract

[1] 
Pasinelli, P.; Brown, R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci.,  2006, 7(9), 710-723.
[http://dx.doi.org/10.1038/nrn1971] [PMID:  16924260] 
[2] 
Kumar, V.; Islam, A.; Hassan, M.I.; Ahmad, F. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning. Eur. J. Med. Chem.,  2016, 121, 903-917.
[http://dx.doi.org/10.1016/j.ejmech.2016.06.017] [PMID:  27372371] 
[3] 
Gil, J.; Funalot, B.; Verschueren, A.; Danel-Brunaud, V.; Camu, W.; Vandenberghe, N.; Desnuelle, C.; Guy, N.; Camdessanche, J.P.; Cintas, P.; Carluer, L.; Pittion, S.; Nicolas, G.; Corcia, P.; Fleury, M.C.; Maugras, C.; Besson, G.; Le Masson, G.; Couratier, P. Causes of death amongst French patients with amyotrophic lateral sclerosis: A prospective study. Eur. J. Neurol.,  2008, 15(11), 1245-1251.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02307.x] [PMID:  18973614] 
[4] 
Spataro, R.; Lo Re, M.; Piccoli, T.; Piccoli, F.; La Bella, V. Causes and place of death in Italian patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.,  2010, 122(3), 217-223.
[http://dx.doi.org/10.1111/j.1600-0404.2009.01290.x] [PMID:  20078446] 
[5] 
Robberecht, W.; Philips, T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci.,  2013, 14(4), 248-264.
[http://dx.doi.org/10.1038/nrn3430] [PMID:  23463272] 
[6] 
Pradas, J.; Puig, T.; Rojas-García, R.; Viguera, M.L.; Gich, I.; Logroscino, G. Amyotrophic lateral sclerosis in Catalonia: A population based study. Amyotroph. Lateral Scler. Frontotemporal Degener.,  2013, 14(4), 278-283.
[http://dx.doi.org/10.3109/21678421.2012.749915] [PMID:  23286747] 
[7] 
Joensen, P. Incidence of amyotrophic lateral sclerosis in the Faroe Islands. Acta Neurol. Scand.,  2012, 126(1), 62-66.
[http://dx.doi.org/10.1111/j.1600-0404.2011.01611.x] [PMID:  22034926] 
[8] 
Chiò, A.; Logroscino, G.; Traynor, B.J.; Collins, J.; Simeone, J.C.; Goldstein, L.A.; White, L.A. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature. Neuroepidemiology,  2013, 41(2), 118-130.
[http://dx.doi.org/10.1159/000351153] [PMID:  23860588] 
[9] 
Wittie, M.; Nelson, L.M.; Usher, S.; Ward, K.; Benatar, M. Utility of capture-recapture methodology to assess completeness of amyotrophic lateral sclerosis case ascertainment. Neuroepidemiology,  2013, 40(2), 133-141.
[http://dx.doi.org/10.1159/000342156] [PMID:  23095852] 
[10] 
Zufiría, M.; Gil-Bea, F.J.; Fernández-Torrón, R.; Poza, J.J.; Muñoz-Blanco, J.L.; Rojas-García, R.; Riancho, J.; López de Munain, A. ALS: A bucket of genes, environment, metabolism and unknown ingredients. Prog. Neurobiol.,  2016, 142, 104-129.
[http://dx.doi.org/10.1016/j.pneurobio.2016.05.004] [PMID:  27236050] 
[11] 
Logroscino, G.; Traynor, B.J.; Hardiman, O.; Chiò, A.; Mitchell, D.; Swingler, R.J.; Millul, A.; Benn, E.; Beghi, E. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry,  2010, 81(4), 385-390.
[http://dx.doi.org/10.1136/jnnp.2009.183525] [PMID:  19710046] 
[12] 
Zaldivar, T.; Gutierrez, J.; Lara, G.; Carbonara, M.; Logroscino, G.; Hardiman, O. Reduced frequency of ALS in an ethnically mixed population: A population-based mortality study. Neurology,  2009, 72(19), 1640-1645.
[http://dx.doi.org/10.1212/WNL.0b013e3181a55f7b] [PMID:  19433736] 
[13] 
Ferraiuolo, L.; Kirby, J.; Grierson, A.J.; Sendtner, M.; Shaw, P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol.,  2011, 7(11), 616-630.
[http://dx.doi.org/10.1038/nrneurol.2011.152] [PMID:  22051914] 
[14] 
Shaw, P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Psychiatry,  2005, 76(8), 1046-1057.
[http://dx.doi.org/10.1136/jnnp.2004.048652] [PMID:  16024877] 
[15] 
Dunkel, P.; Chai, C.L.; Sperlágh, B.; Huleatt, P.B.; Mátyus, P. Clinical utility of neuroprotective agents in neurodegenerative diseases: Current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs,  2012, 21(9), 1267-1308.
[http://dx.doi.org/10.1517/13543784.2012.703178] [PMID:  22741814] 
[16] 
Contestabile, A. Amyotrophic lateral sclerosis: From research to therapeutic attempts and therapeutic perspectives. Curr. Med. Chem.,  2011, 18(36), 5655-5665.
[http://dx.doi.org/10.2174/092986711798347289] [PMID:  22172070] 
[17] 
Al-Saif, A.; Al-Mohanna, F.; Bohlega, S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol.,  2011, 70(6), 913-919.
[http://dx.doi.org/10.1002/ana.22534] [PMID:  21842496] 
[18] 
Swinnen, B.; Robberecht, W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol.,  2014, 10(11), 661-670.
[http://dx.doi.org/10.1038/nrneurol.2014.184] [PMID:  25311585] 
[19] 
Byrne, S.; Walsh, C.; Lynch, C.; Bede, P.; Elamin, M.; Kenna, K.; McLaughlin, R.; Hardiman, O. Rate of familial amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry,  2011, 82(6), 623-627.
[http://dx.doi.org/10.1136/jnnp.2010.224501] [PMID:  21047878] 
[20] 
Al-Chalabi, A.; Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol.,  2013, 9(11), 617-628.
[http://dx.doi.org/10.1038/nrneurol.2013.203] [PMID:  24126629] 
[21] 
Nagoshi, N.; Nakashima, H.; Fehlings, M.G. Riluzole as a neuroprotective drug for spinal cord injury: From bench to bedside. Molecules,  2015, 20(5), 7775-7789.
[http://dx.doi.org/10.3390/molecules20057775] [PMID:  25939067] 
[22] 
Glicksman, M.A. The preclinical discovery of amyotrophic lateral sclerosis drugs. Expert Opin. Drug Discov.,  2011, 6(11), 1127-1138.
[http://dx.doi.org/10.1517/17460441.2011.628654] [PMID:  22646982] 
[23] 
Cruz, M.P. Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P&T,  2018, 43(1), 25-28.
[PMID:  29290672] 
[24] 
Abe, K.; Aoki, M.; Tsuji, S.; Itoyama, Y.; Sobue, G.; Togo, M.; Hamada, C.; Tanaka, M.; Akimoto, M.; Nakamura, K. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol.,  2017, 16(7), 505-512.
[http://dx.doi.org/10.1016/S1474-4422(17)30115-1] [PMID:  28522181] 
[25] 
Mir, R.H.; Sawhney, G.; Verma, R.; Ahmad, B.; Kumar, P.; Ranjana, S.; Bhagat, A.; Madishetti, S.; Ahmed, Z.; Jachak, S.M. Oreganum Vulgare: In-vitro assessment of cytotoxicity, Molecular docking studies, Antioxidant, and evaluation of anti-inflammatory activity	in LPS stimulated RAW 264.7 cells. Medicinal Chemistry:	Shariqah, United Arab Emirates,, 2020.
[26] 
Hassan Mir, R.; Godavari, G.; Siddiqui, N.A.; Ahmad, B.; Mothana, R.A.; Ullah, R.; Almarfadi, O.M.; Jachak, S.M.; Masoodi, M.H. Design, synthesis, molecular modelling, and biological evaluation of oleanolic acid-arylidene derivatives as potential anti-inflammatory agents. Drug Des. Devel. Ther.,  2021, 15, 385-397.
[http://dx.doi.org/10.2147/DDDT.S291784] [PMID:  33574657] 
[27] 
Mohi-Ud-Din, R.; Mir, R.H.; Mir, P.A.; Farooq, S.; Raza, S.N.; Raja, W.Y.; Masoodi, M.H.; Singh, I.P.; Bhat, Z.A. Ethnomedicinal uses, phytochemistry and pharmacological aspects of the genus berberis linn: A comprehensive review. Comb. Chem. High Throughput Screen.,  2021, 24(5), 624-644.
[PMID:  33143603] 
[28] 
Mir, R.H.; Bhat, M.F.; Sawhney, G.; Kumar, P.; Andrabi, N.I.; Shaikh, M.; Mohi-Ud-Din, R.; Masoodi, M.H. Prunella vulgaris L: Critical pharmacological, expository traditional uses and extensive phytochemistry: A review. Curr. Drug Discov. Technol., 2021.
[http://dx.doi.org/10.2174/1570163818666210203181542] [PMID:  33538676] 
[29] 
Hassan, R.; Masoodi, M.H. Saussurea lappa: A comprehensive review on its pharmacological activity and phytochemistry. Curr. Tradit. Med.,  2020, 6(1), 13-23.
[http://dx.doi.org/10.2174/2215083805666190626144909] 
[30] 
Mir, R.H.; Masoodi, M.H. Anti-inflammatory plant polyphenolics and cellular action mechanisms. Curr. Bioact. Compd.,  2020, 16(6), 809-817.
[http://dx.doi.org/10.2174/1573407215666190419205317] 
[31] 
Rates, S.M.K. Plants as source of drugs. Toxicon,  2001, 39(5), 603-613.
[http://dx.doi.org/10.1016/S0041-0101(00)00154-9] [PMID:  11072038] 
[32] 
Mir, R.H.; Shah, A.J.; Mohi-Ud-Din, R.; Pottoo, F.H.; Dar, M.A.; Jachak, S.M.; Masoodi, M.H. Natural anti-inflammatory compounds as drug candidates in Alzheimer’s disease. Curr. Med. Chem.,  2020, 28(23), 4799-4825.
[http://dx.doi.org/10.2174/0929867327666200730213215] [PMID:  32744957] 
[33] 
Van Raamsdonk, J.M.; Vega, I.E.; Brundin, P. Oxidative stress in neurodegenerative disease: Causation or association? Oncotarget,  2017, 8(7), 10777-10778.
[http://dx.doi.org/10.18632/oncotarget.14650] [PMID:  28099897] 
[34] 
Liu, Z.; Zhou, T.; Ziegler, A.C.; Dimitrion, P.; Zuo, L. Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxid. Med. Cell. Longev.,  2017, 20172525967
[http://dx.doi.org/10.1155/2017/2525967] 
[35] 
Singh, A.; Kukreti, R.; Saso, L.; Kukreti, S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules,  2019, 24(8), 1583.
[http://dx.doi.org/10.3390/molecules24081583] [PMID:  31013638] 
[36] 
Rekatsina, M.; Paladini, A.; Piroli, A.; Zis, P.; Pergolizzi, J.V.; Varrassi, G. Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: A narrative review. Adv. Ther.,  2020, 37(1), 113-139.
[http://dx.doi.org/10.1007/s12325-019-01148-5] [PMID:  31782132] 
[37] 
Fukui, K. Reactive oxygen species induce neurite degeneration before induction of cell death. J. Clin. Biochem. Nutr.,  2016, 59(3), 155-159.
[http://dx.doi.org/10.3164/jcbn.16-34] [PMID:  27895381] 
[38] 
Forni, C.; Facchiano, F.; Bartoli, M.; Pieretti, S.; Facchiano, A.; D’Arcangelo, D.; Norelli, S.; Valle, G.; Nisini, R.; Beninati, S. Beneficial role of phytochemicals on oxidative stress and age-related diseases. BioMed Res. Int.,  2019, 78748253
[http://dx.doi.org/10.1155/2019/8748253] 
[39] 
Chico, L.; Ienco, E.C.; Bisordi, C.; Lo Gerfo, A.; Petrozzi, L.; Petrucci, A.; Mancuso, M.; Siciliano, G. Amyotrophic Lateral Sclerosis and oxidative stress: A double-blind therapeutic trial after curcumin supplementation. CNS Neurol. Disord. Drug Targets,  2018, 17(10), 767-779.
[40] 
Bai, J-R.; Liu, Y-J.; Song, Y. The mechanism of interfere effects of madecassoside (MC) on neurodegeneration in mice. Zhongguo Laonianxue Zazhi,  2008, 28, 2297-2300.
[41] 
Kobayashi, Y.; Liu, Y.; Tobinaga, S.; Tsunematsu, T.; Nakamura, M. In journal of pharmacological sciences.Japanese pharmacological
	soc editorial off, kantohya bldg gokomachi, 2007, 103, 136., 
[42] 
Liu, Y. Therapeutic potential of madecassoside in transgenic mice of amyotrophic lateral sclerosis. Chinese Traditional Herbal Drugs,  1994, 5.
[43] 
Liu, S.; Li, G.; Tang, H.; Pan, R.; Wang, H.; Jin, F.; Yan, X.; Xing, Y.; Chen, G.; Fu, Y.; Dong, J. Madecassoside ameliorates lipopolysaccharide-induced neurotoxicity in rats by activating the Nrf2-HO-1 pathway. Neurosci. Lett.,  2019, 709134386
[http://dx.doi.org/10.1016/j.neulet.2019.134386] [PMID:  31330225] 
[44] 
Kumar, V.; Preeti, G.; Md Imtaiyaz, H. Mechanism and implications of traditional Chinese medicine in amyotrophic lateral sclerosis therapy. J. Proteins Proteom.,  2019, 10(2), 131-147.
[45] 
Kambara, T.; Zhou, Y.; Oda, M.; Tamura, Y.; Miyakoshi, M.; Mizutani, K.; Ikeda, T.; Tanaka, O.; Chou, W. 120th Annual Meeting of Pharmaceutical Society of Japan, Gifu2000.
[46] 
Murakami, T.; Miyakoshi, M.; Araho, D.; Mizutani, K.; Kambara, T.; Ikeda, T.; Chou, W-H.; Inukai, M.; Takenaka, A.; Igarashi, K. Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin. Biofactors,  2004, 21(1-4), 175-178.
[http://dx.doi.org/10.1002/biof.552210136] [PMID:  15630194] 
[47] 
Kou, X.; Shen, K.; An, Y.; Qi, S.; Dai, W.X.; Yin, Z. Ampelopsin inhibits H2O2-induced apoptosis by ERK and Akt signaling pathways and up-regulation of heme oxygenase-1. Phytother. Res.,  2012, 26(7), 988-994.
[http://dx.doi.org/10.1002/ptr.3671] [PMID:  22144097] 
[48] 
Kim, T.Y.; Leem, E.; Lee, J.M.; Kim, S.R. Control of reactive oxygen species for the prevention of parkinson’s disease: The possible application of flavonoids. Antioxidants,  2020, 9(7), 583.
[http://dx.doi.org/10.3390/antiox9070583] [PMID:  32635299] 
[49] 
Mandel, S.; Weinreb, O.; Amit, T.; Youdim, M.B. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: Implications for neurodegenerative diseases. J. Neurochem.,  2004, 88(6), 1555-1569.
[http://dx.doi.org/10.1046/j.1471-4159.2003.02291.x] [PMID:  15009657] 
[50] 
Koh, S-H.; Lee, S.M.; Kim, H.Y.; Lee, K-Y.; Lee, Y.J.; Kim, H-T.; Kim, J.; Kim, M-H.; Hwang, M.S.; Song, C.; Yang, K.W.; Lee, K.W.; Kim, S.H.; Kim, O.H. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci. Lett.,  2006, 395(2), 103-107.
[http://dx.doi.org/10.1016/j.neulet.2005.10.056] [PMID:  16356650] 
[51] 
Xu, Z.; Chen, S.; Li, X.; Luo, G.; Li, L.; Le, W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem. Res.,  2006, 31(10), 1263-1269.
[http://dx.doi.org/10.1007/s11064-006-9166-z] [PMID:  17021948] 
[52] 
Hockenbery, D.M.; Oltvai, Z.N.; Yin, X-M.; Milliman, C.L.; Korsmeyer, S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell,  1993, 75(2), 241-251.
[http://dx.doi.org/10.1016/0092-8674(93)80066-N] [PMID:  7503812] 
[53] 
Nabavi, S.F.; Daglia, M.; D’Antona, G.; Sobarzo-Sánchez, E.; Talas, Z.S.; Nabavi, S.M. Natural compounds used as therapies targeting to amyotrophic lateral sclerosis. Curr. Pharm. Biotechnol.,  2015, 16(3), 211-218.
[http://dx.doi.org/10.2174/1389201016666150118132224] [PMID:  25601606] 
[54] 
Srinivasan, E.; Rajasekaran, R. Probing the inhibitory activity of epigallocatechin-gallate on toxic aggregates of mutant (L84F) SOD1 protein through geometry based sampling and steered molecular dynamics. J. Mol. Graph. Model.,  2017, 74, 288-295.
[http://dx.doi.org/10.1016/j.jmgm.2017.04.019] [PMID:  28458007] 
[55] 
Maher, P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int. J. Mol. Sci.,  2019, 20(12), 3056.
[http://dx.doi.org/10.3390/ijms20123056] [PMID:  31234550] 
[56] 
Solanki, I.; Parihar, P.; Parihar, M.S. Neurodegenerative diseases: From available treatments to prospective herbal therapy. Neurochem. Int.,  2016, 95, 100-108.
[http://dx.doi.org/10.1016/j.neuint.2015.11.001] [PMID:  26550708] 
[57] 
Li, P.; Matsunaga, K.; Ohizumi, Y. Nerve growth factor-potentiating compounds from picrorhizae rhizoma. Biol. Pharm. Bull.,  2000, 23(7), 890-892.
[http://dx.doi.org/10.1248/bpb.23.890] [PMID:  10919373] 
[58] 
Cao, Y.; Liu, J.W.; Yu, Y.J.; Zheng, P.Y.; Zhang, X.D.; Li, T.; Guo, M.C. Synergistic protective effect of picroside II and NGF on PC12 cells against oxidative stress induced by H2O2. Pharmacol. Rep.,  2007, 59(5), 573-579.
[PMID:  18048958] 
[59] 
Li, T.; Liu, J-W.; Zhang, X-D.; Guo, M-C.; Ji, G. The neuroprotective effect of picroside II from hu-huang-lian against oxidative stress. Am. J. Chin. Med.,  2007, 35(4), 681-691.
[http://dx.doi.org/10.1142/S0192415X0700517X] [PMID:  17708634] 
[60] 
Guo, N.; Jin, C.; Shen, L.; Wu, F.; Lin, X.; Feng, Y. Chemical components, pharmacological actions, and clinical applications of Rhizoma Picrorhizae. Phytother. Res.,  2020, 34(5), 1071-1082.
[http://dx.doi.org/10.1002/ptr.6591] [PMID:  31880854] 
[61] 
Wang, W.; Xu, J.; Li, L.; Wang, P.; Ji, X.; Ai, H.; Zhang, L.; Li, L. Neuroprotective effect of morroniside on focal cerebral ischemia in rats. Brain Res. Bull.,  2010, 83(5), 196-201.
[http://dx.doi.org/10.1016/j.brainresbull.2010.07.003] [PMID:  20637265] 
[62] 
Wang, W.; Huang, W.; Li, L.; Ai, H.; Sun, F.; Liu, C.; An, Y. Morroniside prevents peroxide-induced apoptosis by induction of endogenous glutathione in human neuroblastoma cells. Cell. Mol. Neurobiol.,  2008, 28(2), 293-305.
[http://dx.doi.org/10.1007/s10571-007-9168-7] [PMID:  17647102] 
[63] 
Wang, W.; Sun, F.; An, Y.; Ai, H.; Zhang, L.; Huang, W.; Li, L. Morroniside protects human neuroblastoma SH-SY5Y cells against hydrogen peroxide-induced cytotoxicity. Eur. J. Pharmacol.,  2009, 613(1-3), 19-23.
[http://dx.doi.org/10.1016/j.ejphar.2009.04.013] [PMID:  19379729] 
[64] 
Zhang, J-X.; Wang, R.; Xi, J.; Shen, L.; Zhu, A-Y.; Qi, Q.; Wang, Q-Y.; Zhang, L-J.; Wang, F-C.; Lü, H-Z.; Hu, J.G. Morroniside protects SK-N-SH human neuroblastoma cells against H2O2-induced damage. Int. J. Mol. Med.,  2017, 39(3), 603-612.
[http://dx.doi.org/10.3892/ijmm.2017.2882] [PMID:  28204825] 
[65] 
Lin, Y.; Lin, B.; Lin, D. Effects of morroniside on the viability of random skin flaps in rats. J. Invest. Surg.,  2020, 33(2), 182-188.
[http://dx.doi.org/10.1080/08941939.2018.1479007] [PMID:  29869899] 
[66] 

 Wang, Shi-bo.; Jing-fu, Qiu.; Qun-hua, B.; Jia-Jia, Li.; Jin-yu, He.;
	Yan-jun G.; and Chao Y. A study on protection of astragaioside IV
	about oxidative stress on PC12 cells induced by H2O2. Chinese
	Pharmacol. Bull.,,  2011, 11
[67] 
Rong, J.; Cheung, C.Y-H.; Lau, A.S-Y.; Shen, J.; Tam, P.K-H.; Cheng, Y-C. Induction of heme oxygenase-1 by traditional Chinese medicine formulation ISF-1 and its ingredients as a cytoprotective mechanism against oxidative stress. Int. J. Mol. Med.,  2008, 21(4), 405-411.
[http://dx.doi.org/10.3892/ijmm.21.4.405] [PMID:  18360685] 
[68] 
Yu, J.; Guo, M.; Li, Y.; Zhang, H.; Chai, Z.; Wang, Q.; Yan, Y.; Yu, J.; Liu, C.; Zhang, G-X. Astragaloside IV protects neurons from microglia-mediated cell damage through promoting microglia polarization. Folia Neuropathol.,  2019, 57(2), 170-181.
[http://dx.doi.org/10.5114/fn.2019.86299] 
[69] 
Shahzad, M.; Shabbir, A.; Wojcikowski, K.; Wohlmuth, H.; Gobe, G.C. The antioxidant effects of Radix Astragali (Astragalus membranaceus and related species) in protecting tissues from injury and disease. Curr. Drug Targets,  2016, 17(12), 1331-1340.
[http://dx.doi.org/10.2174/1389450116666150907104742] [PMID:  26343107] 
[70] 
Zhu, J.; Shen, L.; Lin, X.; Hong, Y.; Feng, Y. Clinical research on traditional chinese medicine compounds and their preparations for amyotrophic lateral sclerosis. Biomed. Pharmacother.,  2017, 96, 854-864.
[http://dx.doi.org/10.1016/j.biopha.2017.09.135] [PMID:  29078263] 
[71] 
Sun, M-M.; Bu, H.; Li, B.; Yu, J-X.; Guo, Y-S.; Li, C-Y. Neuroprotective potential of phase II enzyme inducer diallyl trisulfide. Neurol. Res.,  2009, 31(1), 23-27.
[http://dx.doi.org/10.1179/174313208X332959] [PMID:  18768114] 
[72] 
Guo, Y.; Zhang, K.; Wang, Q.; Li, Z.; Yin, Y.; Xu, Q.; Duan, W.; Li, C. Neuroprotective effects of diallyl trisulfide in SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. Brain Res.,  2011, 1374, 110-115.
[http://dx.doi.org/10.1016/j.brainres.2010.12.014] [PMID:  21147075] 
[73] 
Calò, L.A.; Fusaro, M.; Davis, P.A. HO-1 attenuates hypertension-induced inflammation/oxidative stress: support from Bartter’s/Gitelman’s patients. Am. J. Hypertens.,  2010, 23(9), 936-936.
[http://dx.doi.org/10.1038/ajh.2010.130] [PMID:  20733571] 
[74] 
Liu, C.; Leng, B.; Li, Y.; Jiang, H.; Duan, W.; Guo, Y.; Li, C.; Hong, K. Diallyl trisulfide protects motor neurons from the neurotoxic protein TDP-43 via activating lysosomal degradation and the antioxidant response. Neurochem. Res.,  2018, 43(12), 2304-2312.
[http://dx.doi.org/10.1007/s11064-018-2651-3] [PMID:  30317421] 
[75] 
Silva-Islas, C.A.; Chánez-Cárdenas, M.E.; Barrera-Oviedo, D.; Ortiz-Plata, A.; Pedraza-Chaverri, J.; Maldonado, P.D. Diallyl trisulfide protects rat brain tissue against the damage induced by ischemia-reperfusion through the Nrf2 pathway. Antioxidants,  2019, 8(9), 410.
[http://dx.doi.org/10.3390/antiox8090410] [PMID:  31540440] 
[76] 
Jain, K.K. In The Handbook of Neuroprotection; Springer, 2019, pp. 609-641.
[http://dx.doi.org/10.1007/978-1-4939-9465-6_10] 
[77] 
Weydt, P.; Möller, T. Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Neuroreport,  2005, 16(6), 527-531.
[http://dx.doi.org/10.1097/00001756-200504250-00001] [PMID:  15812300] 
[78] 
Weydt, P.; Weiss, M.D.; Möller, T.; Carter, G.T. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr. Opin. Investig. Drugs,  2002, 3(12), 1720-1724.
[79] 
Subedi, L.; Lee, S.E.; Madiha, S.; Gaire, B.P.; Jin, M.; Yumnam, S.; Kim, S.Y. Phytochemicals against TNFα-mediated neuroinflammatory diseases. Int. J. Mol. Sci.,  2020, 21(3), 764.
[http://dx.doi.org/10.3390/ijms21030764] [PMID:  31991572] 
[80] 
Ong, W.Y.; Farooqui, T.; Ho, C.F.Y.; Ng, Y.K.; Farooqui, A.A. Use of Phytochemicals against neuroinflammation; Neuroprotective Effects of Phytochemicals in Neurological Disorders, 2017, p. 648.
[81] 
Morita, T. Celastrol: A new therapeutic potential of traditional Chinese medicine. Am. J. Hypertens.,  2010, 23(8), 821-821.
[http://dx.doi.org/10.1038/ajh.2010.87] [PMID:  20644533] 
[82] 
Kiaei, M.; Kipiani, K.; Petri, S.; Chen, J.; Calingasan, N.Y.; Beal, M.F. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis.,  2005, 2(5), 246-254.
[http://dx.doi.org/10.1159/000090364] [PMID:  16909005] 
[83] 
Jung, H.W.; Chung, Y.S.; Kim, Y.S.; Park, Y-K. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp. Mol. Med.,  2007, 39(6), 715-721.
[http://dx.doi.org/10.1038/emm.2007.78] [PMID:  18160842] 
[84] 
Venkatesha, S.H.; Dudics, S.; Astry, B.; Moudgil, K.D. Control of autoimmune inflammation by celastrol, a natural triterpenoid. Pathog. Dis.,  2016, 74(6)ftw059
[http://dx.doi.org/10.1093/femspd/ftw059] [PMID:  27405485] 
[85] 
Zhu, Y.; Fotinos, A.; Mao, L.L.; Atassi, N.; Zhou, E.W.; Ahmad, S.; Guan, Y.; Berry, J.D.; Cudkowicz, M.E.; Wang, X. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov. Today,  2015, 20(1), 65-75.
[http://dx.doi.org/10.1016/j.drudis.2014.08.016] [PMID:  25205348] 
[86] 
Zhang, R.; Zhu, Y.; Dong, X.; Liu, B.; Zhang, N.; Wang, X.; Liu, L.; Xu, C.; Huang, S.; Chen, L. Celastrol attenuates cadmium-induced neuronal apoptosis via inhibiting Ca2+ -CaMKII-dependent Akt/mTOR pathway. J. Cell. Physiol.,  2017, 232(8), 2145-2157.
[http://dx.doi.org/10.1002/jcp.25703] [PMID:  27891586] 
[87] 
Burns, J.; Yokota, T.; Ashihara, H.; Lean, M.E.; Crozier, A. Plant foods and herbal sources of resveratrol. J. Agric. Food Chem.,  2002, 50(11), 3337-3340.
[http://dx.doi.org/10.1021/jf0112973] [PMID:  12010007] 
[88] 
Bi, X.L.; Yang, J.Y.; Dong, Y.X.; Wang, J.M.; Cui, Y.H.; Ikeshima, T.; Zhao, Y.Q.; Wu, C.F. Resveratrol inhibits nitric oxide and TNF-α production by lipopolysaccharide-activated microglia. Int. Immunopharmacol.,  2005, 5(1), 185-193.
[http://dx.doi.org/10.1016/j.intimp.2004.08.008] [PMID:  15589480] 
[89] 
Meng, X-L.; Yang, J-Y.; Chen, G-L.; Wang, L-H.; Zhang, L-J.; Wang, S.; Li, J.; Wu, C-F. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. Chem. Biol. Interact.,  2008, 174(1), 51-59.
[http://dx.doi.org/10.1016/j.cbi.2008.04.015] [PMID:  18513711] 
[90] 
Contestabile, A. Oxidative stress in neurodegeneration: mechanisms and therapeutic perspectives. Curr. Top. Med. Chem.,  2001, 1(6), 553-568.
[http://dx.doi.org/10.2174/1568026013394723] [PMID:  11895131] 
[91] 
Mancuso, R.; del Valle, J.; Modol, L.; Martinez, A.; Granado-Serrano, A.B.; Ramirez-Núñez, O.; Pallás, M.; Portero-Otin, M.; Osta, R.; Navarro, X. Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics,  2014, 11(2), 419-432.
[PMID:  24414863] 
[92] 
Yun, Y.C.; Jeong, S.G.; Kim, S.H.; Cho, G.W. Reduced sirtuin 1/adenosine monophosphate-activated protein kinase in amyotrophic lateral sclerosis patient-derived mesenchymal stem cells can be restored by resveratrol. J. Tissue Eng. Regen. Med.,  2019, 13(1), 110-115.
[PMID:  30479062] 
[93] 
ALS Untangled no. 49. Resveratrol. Amyotroph. Lateral Scler. Frontotemporal Degener.,  2019, 20(7-8), 619-624.
[http://dx.doi.org/10.1080/21678421.2019.1593596] [PMID:  30945567] 
[94] 
Laudati, G.; Mascolo, L.; Guida, N.; Sirabella, R.; Pizzorusso, V.; Bruzzaniti, S.; Serani, A.; Di Renzo, G.; Canzoniero, L.M.T.; Formisano, L. Resveratrol treatment reduces the vulnerability of SH-SY5Y cells and cortical neurons overexpressing SOD1-G93A to Thimerosal toxicity through SIRT1/DREAM/PDYN pathway. Neurotoxicology,  2019, 71, 6-15.
[http://dx.doi.org/10.1016/j.neuro.2018.11.009] [PMID:  30503815] 
[95] 
Kaiyan, Y.; Jianlan, G.; Dongmei, Y.; Qin, S. Effect of curcumin on iNOS expression in LPS-activated microglia cells and anti-oxidation., 2010.
[96] 
Yin, W.; Shi, X.; Zhang, X.; Yu, L.  Curcumins upregulate expression
	of HO-1 via inducing Nrf-2 in SH-SY5Y cells. Chinese Pharmacol.
	Bulletin,, 2003.
[97] 
Sikora, E.; Scapagnini, G.; Barbagallo, M. Curcumin, inflammation, ageing and age-related diseases. Immun. Ageing,  2010, 7(1), 1.
[http://dx.doi.org/10.1186/1742-4933-7-1] [PMID:  20205886] 
[98] 
Bedlack, R.; Group, A. ALSUntangled 44. Curcumin. Amyotroph. Lateral Scler. Frontotemporal Degener.,  2018, 19(7-8), 623-629.
[http://dx.doi.org/10.1080/21678421.2018.1440738] [PMID:  29493344] 
[99] 
Chico, L.; Ienco, E.C.; Bisordi, C.; Gerfo, A.L.; Schirinzi, E.; Siciliano, G. Curcumin as an ROS scavenger in amyotrophic lateral sclerosis. React. Oxygen Species,  2016, 2(5), 339-354.
[100] 
Adami, R.; Bottai, D. Curcumin and neurological diseases. Nutr. Neurosci.,  2020, 1-21.
[http://dx.doi.org/10.1080/1028415X.2020.1760531] [PMID:  32441587] 
[101] 
Yuan, D.; Ma, B.; Yang, J.Y.; Xie, Y.Y.; Wang, L.; Zhang, L.J.; Kano, Y.; Wu, C.F. Anti-inflammatory effects of rhynchophylline and isorhynchophylline in mouse N9 microglial cells and the molecular mechanism. Int. Immunopharmacol.,  2009, 9(13-14), 1549-1554.
[http://dx.doi.org/10.1016/j.intimp.2009.09.010] [PMID:  19781666] 
[102] 
Song, Y.; Liu, J.; Shi, F.; Lan, Z.; Li, L.; Ma, S. Inhibitory effect of isorhynchophylline on lipopolysaccharide stimulated release of inflammatory mediators in primary rat astrocytes. Pharmacol Clin Res,  2011, 19(2), 311-314.
[103] 
Rahman, M.A.; Rahman, M.R.; Zaman, T.; Uddin, M.S.; Islam, R.; Abdel-Daim, M.M.; Rhim, H. Emerging potential of naturally occurring autophagy Modulators against neurodegeneration. Curr. Pharm. Des.,  2020, 26(7), 772-779.
[http://dx.doi.org/10.2174/1381612826666200107142541] [PMID:  31914904] 
[104] 
Ock, J.; Han, H.S.; Hong, S.H.; Lee, S.Y.; Han, Y.M.; Kwon, B.M.; Suk, K. Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br. J. Pharmacol.,  2010, 159(8), 1646-1662.
[http://dx.doi.org/10.1111/j.1476-5381.2010.00659.x] [PMID:  20397299] 
[105] 
Liu, J.; Su, G.; Gao, J.; Tian, Y.; Liu, X.; Zhang, Z. Effects of peroxiredoxin 2 in neurological disorders: A review of its molecular mechanisms. Neurochem. Res.,  2020, 45(4), 720-730.
[http://dx.doi.org/10.1007/s11064-020-02971-x] [PMID:  32002772] 
[106] 
Rehman, M.U.; Wali, A.F.; Ahmad, A.; Shakeel, S.; Rasool, S.; Ali, R.; Rashid, S.M.; Madkhali, H.; Ganaie, M.A.; Khan, R. Neuroprotective strategies for neurological disorders by natural products: An update. Curr. Neuropharmacol.,  2019, 17(3), 247-267.
[http://dx.doi.org/10.2174/1570159X16666180911124605] [PMID:  30207234] 
[107] 
Tseng, Y-T.; Hsu, Y-Y.; Shih, Y-T.; Lo, Y-C. Paeonol attenuates microglia-mediated inflammation and oxidative stress-induced neurotoxicity in rat primary microglia and cortical neurons. Shock,  2012, 37(3), 312-318.
[http://dx.doi.org/10.1097/SHK.0b013e31823fe939] [PMID:  22089194] 
[108] 
Wang, X.; Zhu, G.; Yang, S.; Wang, X.; Cheng, H.; Wang, F.; Li, X.; Li, Q. Paeonol prevents excitotoxicity in rat pheochromocytoma PC12 cells via downregulation of ERK activation and inhibition of apoptosis. Planta Med.,  2011, 77(15), 1695-1701.
[http://dx.doi.org/10.1055/s-0030-1271033] [PMID:  21509715] 
[109] 
He, L.X.; Tong, X.; Zeng, J.; Tu, Y.; Wu, S.; Li, M.; Deng, H.; Zhu, M.; Li, X.; Nie, H.; Yang, L.; Huang, F. Paeonol suppresses neuroinflammatory responses in LPS-activated microglia cells. Inflammation,  2016, 39(6), 1904-1917.
[http://dx.doi.org/10.1007/s10753-016-0426-z] [PMID:  27624059] 
[110] 
Lee, H.; Kim, Y.O.; Kim, H.; Kim, S.Y.; Noh, H.S.; Kang, S.S.; Cho, G.J.; Choi, W.S.; Suk, K. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J.,  2003, 17(13), 1943-1944.
[http://dx.doi.org/10.1096/fj.03-0057fje] [PMID:  12897065] 
[111] 
Piao, H.; Cui, H.; Piao, R.; Yingjun, L. Effects of wogonin on LPS-induced production of proinflammatory cytokines. J. Xi’an Jiaotong University; Medical Sciences, 1981, p. 2.
[112] 
Zhang, J.; He, Y.; Jiang, X.; Jiang, H.; Shen, J. Nature brings new avenues to the therapy of central nervous system diseases-An overview of possible treatments derived from natural products. Sci. China Life Sci.,  2019, 62(10), 1332-1367.
[http://dx.doi.org/10.1007/s11427-019-9587-y] [PMID:  31444682] 
[113] 
Li, Y.; Liu, S.; Zhang, H.; Zhou, F.; Liu, Y.; Lu, Q.; Yang, L. Antioxidant effects of celastrol against hydrogen peroxide-induced oxidative stress in the cell model of amyotrophic lateral sclerosis. Sheng Li Xue Bao,  2017, 69(6), 751.
[114] 
Deane, C.A.; Brown, I.R. Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol. Cell Stress Chaperones,  2016, 21(5), 837-848.
[http://dx.doi.org/10.1007/s12192-016-0708-2] [PMID:  27273088] 
[115] 
Kim, D.; Nguyen, M.D.; Dobbin, M.M.; Fischer, A.; Sananbenesi, F.; Rodgers, J.T.; Delalle, I.; Baur, J.A.; Sui, G.; Armour, S.M.; Puigserver, P.; Sinclair, D.A.; Tsai, L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J.,  2007, 26(13), 3169-3179.
[http://dx.doi.org/10.1038/sj.emboj.7601758] [PMID:  17581637] 
[116] 
Wang, J.; Zhang, Y.; Tang, L.; Zhang, N.; Fan, D. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci. Lett.,  2011, 503(3), 250-255.
[http://dx.doi.org/10.1016/j.neulet.2011.08.047] [PMID:  21896316] 
[117] 
Markert, C.D.; Kim, E.; Gifondorwa, D.J.; Childers, M.K.; Milligan, C.E. A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J. Med. Food,  2010, 13(5), 1081-1085.
[http://dx.doi.org/10.1089/jmf.2009.0243] [PMID:  20626250] 
[118] 
Mancuso, R.; Del Valle, J.; Morell, M.; Pallás, M.; Osta, R.; Navarro, X. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: Overlapping effects or limited therapeutic opportunity? Orphanet J. Rare Dis.,  2014, 9(1), 78.
[http://dx.doi.org/10.1186/1750-1172-9-78] [PMID:  24885036] 
[119] 
Dong, H.; Xu, L.; Wu, L.; Wang, X.; Duan, W.; Li, H.; Li, C. Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS. Neuroscience,  2014, 272, 141-153.
[http://dx.doi.org/10.1016/j.neuroscience.2014.04.032] [PMID:  24785678] 
[120] 
Zhang, X.; Hong, Y.L.; Xu, D.S.; Feng, Y.; Zhao, L.J.; Ruan, K.F.; Yang, X.J. A review of experimental research on herbal compounds in amyotrophic lateral sclerosis. Phytother. Res.,  2014, 28(1), 9-21.
[http://dx.doi.org/10.1002/ptr.4960] [PMID:  23519768] 
[121] 
Kaneko, Y.; Coats, A.B.; Tuazon, J.P.; Jo, M.; Borlongan, C.V. Rhynchophylline promotes stem cell autonomous metabolic homeostasis. Cytotherapy,  2020, 22(2), 106-113.
[http://dx.doi.org/10.1016/j.jcyt.2019.12.008] [PMID:  31983606] 
[122] 
Wang, Y-H.; Zeng, K-W. Natural products as a crucial source of anti-inflammatory drugs: Recent trends and advancements. Trad. Med. Res.,  2019, 4(5), 257-268.
[123] 
Lee, S-H.; Suk, K. Identification of glia phenotype modulators based on select glial function regulatory signaling pathways. Expert Opin. Drug Discov.,  2018, 13(7), 627-641.
[http://dx.doi.org/10.1080/17460441.2018.1465925] [PMID:  29676181] 
[124] 
Zhu, Y.; Wang, J. Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: Potential drug to treat Alzheimer’s disease. Neurol. Sci.,  2015, 36(7), 1181-1188.
[http://dx.doi.org/10.1007/s10072-015-2070-z] [PMID:  25596147] 
[125] 
Yousuf, M.; Khan, P.; Shamsi, A.; Shahbaaz, M.; Hasan, G.M.; Haque, Q.M.R.; Christoffels, A.; Islam, A.; Hassan, M.I. Inhibiting CDK6 activity by quercetin is an attractive strategy for cancer therapy. ACS Omega,  2020, 5(42), 27480-27491.
[http://dx.doi.org/10.1021/acsomega.0c03975] [PMID:  33134711] 
[126] 
von Lewinski, F.; Keller, B.U. Ca2+, mitochondria and selective motoneuron vulnerability: Implications for ALS. Trends Neurosci.,  2005, 28(9), 494-500.
[http://dx.doi.org/10.1016/j.tins.2005.07.001] [PMID:  16026864] 
[127] 
Appel, S.H.; Beers, D.; Siklos, L.; Engelhardt, J.I.; Mosier, D.R. Calcium: The darth vader of ALS. Amyotroph. Lateral Scler. Other Motor Neuron Disord.,  2001, 2(1)(Suppl. 1), S47-S54.
[PMID:  11465925] 
[128] 
Prell, T.; Lautenschläger, J.; Grosskreutz, J. Calcium-dependent protein folding in amyotrophic lateral sclerosis. Cell Calcium,  2013, 54(2), 132-143.
[http://dx.doi.org/10.1016/j.ceca.2013.05.007] [PMID:  23764168] 
[129] 
Chen, D-M.; Xiao, L.; Cai, X.; Zeng, R.; Zhu, X-Z. Involvement of multitargets in paeoniflorin-induced preconditioning. J. Pharmacol. Exp. Ther.,  2006, 319(1), 165-180.
[http://dx.doi.org/10.1124/jpet.106.104380] [PMID:  16840647] 
[130] 
Mao, Q.Q.; Zhong, X.M.; Li, Z.Y.; Huang, Z. Paeoniflorin protects against NMDA-induced neurotoxicity in PC12 cells via Ca2+ antagonism. Phytother. Res.,  2011, 25(5), 681-685.
[http://dx.doi.org/10.1002/ptr.3321] [PMID:  21043034] 
[131] 
Yang, J.; He, L.N.; He, S.B. Effect of paeoniflorin on calcium overloading injury in cultured PC12 cells. Zhongguo Xin Yao Zazhi,  2001, 6, 413-416.
[132] 
Mao, Q-Q.; Zhong, X-M.; Feng, C-R.; Pan, A-J.; Li, Z-Y.; Huang, Z. Protective effects of paeoniflorin against glutamate-induced neurotoxicity in PC12 cells via antioxidant mechanisms and Ca(2+) antagonism. Cell. Mol. Neurobiol.,  2010, 30(7), 1059-1066.
[http://dx.doi.org/10.1007/s10571-010-9537-5] [PMID:  20577899] 
[133] 
da S Hage-Melim, L.I.; Ferreira, J.V.; de Oliveira, N.K.; Correia, L.C.; Almeida, M.R.; Poiani, J.G.; Taft, C.A.; de Paula da Silva, C.H. The impact of natural compounds on the treatment of neurodegenerative diseases. Curr. Org. Chem.,  2019, 23(3), 335-360.
[134] 
Zhang, L-C. Paeoniflorin reduces the spinal cord injury in rats through TLR4 inflammatory pathway and Nrf2 oxidative stress pathway: The experimental study. Hainan Yixueyuan Xuebao,  2017, 23(8), 26-30.
[135] 
Yifeng, D.; Zhaolin, S.; Yang, L.; Zhongyan, H.; Shuli, S. Effects of ligustrazine on L-type calcium current in SH-SY5Y human neuroblastoma. Chinese J. Neuroimmunol. Neurol.,  2004, 11(1), 43-45.
[136] 
Masoomzadeh, S.; Aminroaia, P.; Darchin Tabrizi, F.; Rashvand, S.; Rostamizadeh, K. Lipid based nanoparticles for treatment of CNS diseases. Nanomed. Res. J.,  2020, 5(2), 101-113.
[137] 
Li, Y-M.; Chen, F-P.; Liu, G-Q. Studies on inhibitive effect of gastrodin on PC12 cell damage induced by glutamate and H~ 2O~ 2. Zhongguo Yaoke Daxue Xuebao,  2003, 34(5), 456-460.
[138] 
Xu, X.; Lu, Y.; Bie, X. Protective effects of gastrodin on hypoxia-induced toxicity in primary cultures of rat cortical neurons. Planta Med.,  2007, 73(7), 650-654.
[http://dx.doi.org/10.1055/s-2007-981523] [PMID:  17583824] 
[139] 
Du, F.; Wang, X.; Shang, B.; Fang, J.; Xi, Y.; Li, A.; Diao, Y. Gastrodin ameliorates spinal cord injury via antioxidant and anti-inflammatory effects. Acta Biochim. Pol.,  2016, 63(3), 589-593.
[http://dx.doi.org/10.18388/abp.2016_1272] [PMID:  27474401] 
[140] 
Sun, R.; Zhang, Z.; Huang, W.; Lv, L.; Yin, J. Protective effects and machanism of muskone on pheochromocytoma cell injure induced by glutamate. Zhongguo Zhongyao Zazhi,  2009, 34(13), 1701-1704.
[PMID:  19873786] 
[141] 
Van Damme, P.; Dewil, M.; Robberecht, W.; Van Den Bosch, L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener. Dis.,  2005, 2(3-4), 147-159.
[http://dx.doi.org/10.1159/000089620] [PMID:  16909020] 
[142] 
Rosenblum, L.T. Trotti, D. Glial Amino Acid Transporters; Springer, 2017, pp. 117-136.
[http://dx.doi.org/10.1007/978-3-319-55769-4_6] 
[143] 
Malik, A.R.; Willnow, T.E. Excitatory amino acid transporters in physiology and disorders of the central nervous system. Int. J. Mol. Sci.,  2019, 20(22), 5671.
[http://dx.doi.org/10.3390/ijms20225671] [PMID:  31726793] 
[144] 
Cho, J.; Kim, Y.H.; Kong, J-Y.; Yang, C.H.; Park, C.G. Protection of cultured rat cortical neurons from excitotoxicity by asarone, a major essential oil component in the rhizomes of Acorus gramineus. Life Sci.,  2002, 71(5), 591-599.
[http://dx.doi.org/10.1016/S0024-3205(02)01729-0] [PMID:  12052443] 
[145] 
Chen, Y.; Fang, Y.; Liang, Y.; Wang, Q.; He, Y. Protective effects of β-asarone on PC12 cells damage induced by glutamate. Zhongguo Zhongyiyao Xinxi Zazhi,  2007, 14, 22-23.
[146] 
Zheng, M.; Fan, D. Different distribution of NMDA receptor subunits in cortex contributes to selective vulnerability of motor neurons in amyotrophic lateral sclerosis. Beijing Da Xue Xue Bao,  2011, 43(2), 228-233.
[147] 
Deolankar, S.C.; Modi, P.K.; Subbannayya, Y.; Pervaje, R.; Prasad, T.S.K. Molecular targets from traditional medicines for neuroprotection in human neurodegenerative diseases. OMICS,  2020, 24(7), 394-403.
[http://dx.doi.org/10.1089/omi.2020.0033] [PMID:  32486962] 
[148] 
Gordon, R.K.; Nigam, S.V.; Weitz, J.A.; Dave, J.R.; Doctor, B.P.; Ved, H.S. The NMDA receptor ion channel: A site for binding of Huperzine A. J. Appl. Toxicol.,  2001, 21(S1)(Suppl. 1), S47-S51.
[http://dx.doi.org/10.1002/jat.805] [PMID:  11920920] 
[149] 
Hemendinger, R.A.; Armstrong, E.J., III; Persinski, R.; Todd, J.; Mougeot, J-L.; Volvovitz, F.; Rosenfeld, J. Huperzine a provides neuroprotection against several cell death inducers using In-vitro model systems of motor neuron cell death. Neurotox. Res.,  2008, 13(1), 49-61.
[http://dx.doi.org/10.1007/BF03033367] [PMID:  18367440] 
[150] 
Kumar, S.S. Application of phytochemicals for the treatment of neurodegenerative diseases.Drug Invention Today,,  2018, 10(3)
[151] 
Jiang, B.; Liu, J.H.; Bao, Y.M.; An, L.J. Catalpol inhibits apoptosis in hydrogen peroxide-induced PC12 cells by preventing cytochrome c release and inactivating of caspase cascade. Toxicon,  2004, 43(1), 53-59.
[http://dx.doi.org/10.1016/j.toxicon.2003.10.017] [PMID:  15037029] 
[152] 
Wang, J.; Kang, B.; Hu, Y. XIA, Z.-q. Catalpol attenuates PC12 cells injury induced by L-glutamate. Zhongguo Yaolixue Tongbao,  2008, 24, 1258-1259.
[153] 
Zheng, X-w.; Yang, W-t.; Chen, S.; Xu, Q-q.; Shan, C-s.; Zheng, G-q.; Ruan, J-c. Neuroprotection of catalpol for experimental acute focal ischemic stroke: Preclinical evidence and possible mechanisms of antioxidation, anti-inflammation, and antiapoptosis. Oxid. Med. Cell. Longev.,  2017, 20175058609
[154] 
Liu, R.; Liu, J-f.; Xu, K-p. ZOU, H.; SONG, L.-y.; DANG, R.-L.; ZOU, Z.-x.; LI, G.; TAN, G.-s. Chemical constituents in Selaginella tamariscina. Cent. South Pharm.,  2011, 9(8), 564-566.
[155] 
Wang, C-J.; Hu, C-P.; Xu, K-P.; Yuan, Q.; Li, F-S.; Zou, H.; Tan, G-S.; Li, Y-J. Protective effect of selaginellin on glutamate-induced cytotoxicity and apoptosis in differentiated PC12 cells. Naunyn Schmiedebergs Arch. Pharmacol.,  2010, 381(1), 73-81.
[http://dx.doi.org/10.1007/s00210-009-0470-4] [PMID:  19936711] 
[156] 
Pérez-Hernández, J.; Zaldívar-Machorro, V.J.; Villanueva-Porras, D.; Vega-Ávila, E.; Chavarría, A. A potential alternative against neurodegenerative diseases. Phytodrugs. Oxid. Med. Cell. Longev.,  2016, 20168378613
[157] 
Yi, D.; Ning, W.; Quan, Z. Neuroprotective effects of ferulic acid against glutamate-induced neurotoxicity in PC12 cells; Pharmacol. Clin. Chinese Materia Medica, 2008, p. 6.
[158] 
Jin, Y.; Yan, E.Z.; Fan, Y.; Guo, X.L.; Zhao, Y.J.; Zong, Z.H.; Liu, Z. Neuroprotection by sodium ferulate against glutamate-induced apoptosis is mediated by ERK and PI3 kinase pathways. Acta Pharmacol. Sin.,  2007, 28(12), 1881-1890.
[http://dx.doi.org/10.1111/j.1745-7254.2007.00634.x] [PMID:  18031600] 
[159] 
Luo, L.; Sun, Y. Neuroprotective effect of ferulic acid In-vitro. Zhong Yao Cai,  2011, 34(11), 1750-1753.
[PMID:  22506403] 
[160] 
Holeček, V.; Rokyta, R. Possible etiology and treatment of amyotrophic lateral sclerosis. Neuroendocrinol. Lett.,  2018, 38(8), 528-531.
[PMID:  29504729] 
[161] 
Zhang, F.; Zheng, W.; Pi, R.; Mei, Z.; Bao, Y.; Gao, J.; Tang, W.; Chen, S.; Liu, P. Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Exp. Brain Res.,  2009, 193(1), 109-118.
[http://dx.doi.org/10.1007/s00221-008-1600-9] [PMID:  18936923] 
[162] 
Kanekura, K.; Hashimoto, Y.; Kita, Y.; Sasabe, J.; Aiso, S.; Nishimoto, I.; Matsuoka, M.A. Rac1/phosphatidylinositol 3-kinase/Akt3 anti-apoptotic pathway, triggered by AlsinLF, the product of the ALS2 gene, antagonizes Cu/Zn-superoxide dismutase (SOD1) mutant-induced motoneuronal cell death. J. Biol. Chem.,  2005, 280(6), 4532-4543.
[http://dx.doi.org/10.1074/jbc.M410508200] [PMID:  15579468] 
[163] 
Fang, X. Impaired tissue barriers as potential therapeutic targets for Parkinson’s disease and amyotrophic lateral sclerosis. Metab. Brain Dis.,  2018, 33(4), 1031-1043.
[http://dx.doi.org/10.1007/s11011-018-0239-x] [PMID:  29681010] 
[164] 
Chandran, G. Insights on the neuromodulatory propensity of Selaginella (Sanjeevani) and its potential pharmacological applications. CNS Neurol. Disord. Drug Targets,  2014, 13(1), 82-95.
[165] 
Ren, Z.; Zhang, R.; Li, Y.; Li, Y.; Yang, Z.; Yang, H. Ferulic acid exerts neuroprotective effects against cerebral ischemia/reperfusion-induced injury via antioxidant and anti-apoptotic mechanisms in vitro and in vivo. Int. J. Mol. Med.,  2017, 40(5), 1444-1456.
[http://dx.doi.org/10.3892/ijmm.2017.3127] [PMID:  28901374] 
Cite As
Current Neuropharmacology

Plant-Derived Natural Compounds for the Treatment of Amyotrophic Lateral Sclerosis: An Update

Abstract

Graphical Abstract
